Company Description
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors.
The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette"guérin therapy.
Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Dr. Elisabet de los Pinos Ph.D. |
Contact Details
Address: 80 Guest Street Boston, Massachusetts 01235 United States | |
| Phone | (617)500-8864 |
| Website | aurabiosciences.com |
Stock Details
| Ticker Symbol | AURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001501796 |
| CUSIP Number | 05153U107 |
| ISIN Number | US05153U1079 |
| Employer ID | 32-0271970 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Elisabet de los Pinos Ph.D. | Founder, Chief Executive Officer, President and Director |
| Julie B. Feder | Chief Financial Officer, Secretary and Treasurer |
| Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technology Officer |
| Patrick Nealon | Senior Vice President of Clinical Development Operations |
| Dr. Bruce Brown M.D. | Senior Vice President and Therapeutic Area Head of Urologic Oncology |
| Dr. Anthony Daniels M.D. | Therapeutic Area Head of Ocular Oncology |
| Dr. Richard Mountfield Ph.D. | Senior Vice President of Regulatory Affairs and Quality |
| Dr. Jill J. Hopkins M.D. | Chief Medical Officer and President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 15, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 5, 2024 | EFFECT | Notice of Effectiveness |
| Apr 3, 2024 | UPLOAD | Filing |
| Mar 27, 2024 | S-3 | Registration statement under Securities Act of 1933 |